O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up by Cesaretti, C. et al.
ORAL PRESENTATION Open Access
O034. Type of pain and onabotulinumtoxin-A in
chronic migraine: four years of follow-up
Chiara Cesaretti1,2*, Elisabetta Molesti1,2, Francesco Lolli1,3, Aldo Amantini1,2, Silvia Lori1,2
From Abstracts from the 1st Joint ANIRCEF-SISC Congress
Rome, Italy. 29-31 October 2015
Background
Refractory chronic migraine (rCM) [1] is a debilitating
neurological disorder, characterized by headache on ≥ 15
days per month for > 3 months, resistant to conventional
symptomatic and/or prophylactic polytherapy. The effec-
tiveness of the OnabotulinumtoxinA (OnabotA) was
demonstrated in PREEMPT trials and approved in 2010
for CM treatment [2,3]. The prophylactic pharmacological
actions of OnabotA include: a direct antinociceptive-
analgesic effect for primary peripheral afferent terminals
by inhibiting release of nociceptive mediators (glutamate,
substance P, CGRP) [4] and an indirect effect presumed to
involve inhibition of peripheral and central sensitization in
trigeminovascular neurons. The purpose of this study was
to evaluate the efficacy, safety and tolerability of OnabotA
as a prophylactic therapy in patients with rCM and
observe the influence of the type of pain on the effective-
ness of the treatment itself.
Materials and methods
We analyzed 76 patients (64 F), mean age 52 years (23-
82 yr) with rCM referred to the RRCCD of the Careggi
Hospital, between 2011-2014. The patients were treated
(after informed consent) with OnabotA injection in 31/39
sites at the total dosage of 155/195U every 3 months,
according to the PREEMPT protocol. The frequency of
headache days (F), intensity of pain (I) and the consump-
tion of drugs (D) were measured using a Headache Diary.
Two groups of patient were identified by the type of pain
reported: type 1 (severe unilateral) and type 2 (moderate
bilateral) [5]. For statistical analysis we used ANOVA for
repeated measures and the T-test.
Results
All 76 patients received the toxin treatment at least four
times (a one-year follow-up). Of these 44/76 responded
to treatment (38 F). The parameters F, I, D showed a
progressive and gradual decline with time (p 0.001 for
each variable), reaching the maximum effect from the
fourth treatment. The F and D were statistically signifi-
cantly reduced in both groups, more in patients with
type 1 pain (p < 0.001), while the I group was found to
ameliorate without a difference between the different
pain type groups. There were no changes for age, sex
and menstrual cycle. Only one patient (1.3%) dropped
out of the study because of neck pain.
Conclusions
In our four years of follow-up study a high percentage of
rCM patients (58%) showed an improvement in the quality
of life with a reduction of F, I and D. The kind of pain in
migraine patients affects the efficacy of the treatment itself,
and is more successful in patients with type 1 pain in
respect to patients with type 2 pain. OnabotA is a safe
treatment, well tolerated and effective as a prophylactic
treatment in rCM.
Written informed consent to publication was obtained
from the patient(s).
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